Phase 3
Completed N=130
Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
ST-Elevation Myocardial Infarction · NSTEMI - Non-ST Segment Elevation MI
Source: ClinicalTrials.gov NCT03822377 ↗
Enrolled (actual)
130
Serious AEs
0.8%
Results posted
Sep 2021
Primary outcomePrimary: Evaluation of Platelet Inhibition — 94; 141 P2Y12 Reaction Units (PRU)
◆ Published Evidence
Emerging
12citations · ~2 / year
Orodispersible Ticagrelor in Acute Coronary Syndromes: The TASTER Study.
Summary
Randomized clinical study evaluating superiority in platelet inhibition after administration of Ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated tablets in patients admitted for ST elevation myocardial infarction or very high-risk non-ST elevation myocardial infarction.
Linked Publications
-
Orodispersible Ticagrelor in Acute Coronary Syndromes: The TASTER Study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Evaluation of Platelet Inhibition |
94; 141 | — |
| SECONDARY Percent of Patients With Insufficient Antiaggregation |
51; 53 | — |
| SECONDARY Number of Participants With Residual Platelet Reactivity at Various Timepoints |
42; 9 | — |
| SECONDARY Number of Participants With Clinically Relevant Bleeding Events |
0; 4 | — |
Eligibility Criteria
Inclusion Criteria
- Patients presenting within 12 hours from the onset of symptoms with STEMI or very high-risk NSTEMI referred for immediate (< 2 hours) angiography. Very high-risk NSTEMI patients include patients with haemodynamic instability or cardiogenic shock, heart failure, life-threatening arrhythmias or resuscitated cardiac arrest, intermittent ST-segment elevation, or ongoing chest pain.
- Informed, written consent
- Male or female patients, aged ≥ 18 years old
Exclusion Criteria
- Age < 18 years
- Active bleeding; bleeding diathesis; coagulopathy
- History of gastrointestinal or genitourinary bleeding <2 months
- Major surgery in the last 6 weeks
- History of intracranial bleeding or structural abnormalities
- Suspected aortic dissection
- Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux.
- Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic window
- Known relevant hematological deviations: Hb <10 g/dl, Thromb. <100x10^9/l
- Use of warfarin or new oral anticoagulant derivatives within the last 7 days
- Known severe liver disease, severe renal failure
- Allergy or hypersensitivity to ticagrelor or any of the excipients.
- Pregnancy or lactation
Data sourced from ClinicalTrials.gov (NCT03822377) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.